Key Points {#FPar1}
==========

The meta-analyses demonstrated that, for patients with atherosclerotic cardiovascular disease (ASCVD), ezetimibe added to statin therapy provided an additional reduction of 22 mg/dL in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy.LDL-C \> 70 mg/dL is considered a threshold at which additional LDL-C-lowering therapy may be needed in patients with ASCVD and at very high risk of recurrent events; the magnitude of the incremental reduction in LDL-C with ezetimibe observed here may not be sufficient for many patients.

Introduction {#Sec1}
============

Patients with atherosclerotic cardiovascular disease (ASCVD) are at high risk of cardiovascular events \[[@CR1]\], and those with a recent history of a cardiovascular event (within the previous 12 months) are at even greater risk of a recurrent event \[[@CR2]--[@CR6]\]. Patients with clinical ASCVD are typically defined as those with acute coronary syndrome (ACS) or history of myocardial infarction, stable or unstable angina, coronary revascularization, ischemic stroke, transient ischemic attack, or peripheral arterial disease \[[@CR7]\]. Reduction of low-density lipoprotein cholesterol (LDL-C) is recommended to prevent future cardiovascular events.

The 2018 multi-society guideline on the management of blood cholesterol recommended the use of maximally tolerated statins for LDL-C reduction in patients with ASCVD \[[@CR8]\]. However, even with statin therapy, many patients with clinical ASCVD will need additional lipid-lowering therapies (LLTs) to achieve LDL-C levels \< 70 mg/dL \[[@CR9]\]. In fact, for those with ASCVD at very high risk for future events, the guidelines recommended additional LDL-C-lowering therapies (ezetimibe and/or proprotein convertase subtilisin/kexin type 9 \[PCSK9\] inhibitors) if LDL-C is \> 70 mg/dL with maximally tolerated statins.

Ezetimibe is a cholesterol absorption inhibitor that has been shown to provide a 17--23% further reduction in LDL-C levels when added to statin therapy \[[@CR10]--[@CR12]\] and also a reduction of cardiovascular events in patients with ACS in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) \[[@CR12]\]. Patients with ACS are particularly at risk of recurrent cardiovascular events, with approximately 20% recurrence in the first year, as demonstrated by an analysis of clinical registry data \[[@CR4]\].

Although results of individual trials with ezetimibe are available, a comprehensive appraisal of the literature on the LDL-C-lowering efficacy of ezetimibe since IMPROVE-IT is lacking. There is also no review focusing on studies of the recent ACS population. In an effort to address these gaps, we conducted a systematic literature review and meta-analyses to assess the LDL-C-lowering efficacy of ezetimibe in patients with ASCVD and the high-risk subgroup of patients with recent (event in the last 1 year) ACS.

Methods {#Sec2}
=======

We conducted a systematic literature review to find randomized controlled trials (RCTs) that measured the impact of ezetimibe on lowering LDL-C. Meta-analyses were then conducted to assess LDL-C lowering among patients with ASCVD and/or ACS. Sensitivity analyses were conducted to assess the impact of analytic decisions on the primary results.

Literature Sources {#Sec3}
------------------

We searched three electronic bibliographic databases: MEDLINE (via the PubMed platform), Embase (via OVID), and the Cochrane Central Database of Controlled Trials (via the Wiley platform). The databases were searched for all publications from starting date through to 27 August 2018 for MEDLINE and to 28 August 2018 for Embase and the Cochrane Central Database of Controlled Trials. A manual search was also conducted on the reference lists of identified eligible studies and published systematic literature reviews (using the same timeframe as the literature searches for eligible RCTs). In addition, we searched conference abstracts listed in Embase and manually searched specific congress proceedings (a complete list of the congress proceedings searched is provided in the Electronic Supplementary Material \[ESM\]). Congresses were searched from January 2015 through August 2018, inclusive. The search criteria for each database are provided in Tables S1--S3 in the ESM.

Eligibility Criteria {#Sec4}
--------------------

Study eligibility was guided by methods published by The Cochrane Collaboration \[[@CR13]\]. RCTs, of any setting, reported in English, and reporting the population, intervention, comparison, and outcomes of interest (as described below) were eligible for inclusion if they had a follow-up of ≥ 30 days and reported LDL-C outcomes at ≥ 30 days following initiation of treatment. Studies were excluded if they did not meet these eligibility criteria; we also excluded duplicate publications, in vitro studies, animal studies, and studies not reporting LDL-C outcomes by ezetimibe initiation status.

The target population consisted of patients with ASCVD, defined as those with a prior history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease. The LDL-C-lowering intervention assessed was ezetimibe therapy, received with or without other LLTs. Primary efficacy outcomes of interest included the mean change in LDL-C from baseline at 6 months, with sensitivity analyses at 1-, 3-, 9-, and 12-month timepoints (or closest reported timepoint to those).

Study Selection {#Sec5}
---------------

Two reviewers independently screened the identified literature, based on the abovementioned eligibility criteria, in a two-step process: (1) title/abstract screening and (2) full-text screening. If concordance between the two reviewers was below 80% for the title/abstract screen, then the entire bibliography was to be re-screened; however, a re-screen was unnecessary as concordance was 94.6%. After removing duplicates, a full-text screen was performed on the references identified from the title/abstract screening. Reasons provided for inclusion/exclusion of studies at both stages were documented during screening. Any discrepancies that occurred during title/abstract screening or full-text screening were identified and resolved by a third independent reviewer.

Data Extraction {#Sec6}
---------------

Data were extracted by two analysts utilizing the DOC^™^ DATA software platform (version 2.0, Doctor Evidence, LLC, Santa Monica, CA, USA), and any discrepancy was resolved by a third independent reviewer. Data and meta-data were obtained from the text manually, and digitizer software (Grab-It™) was used to capture relevant data points from figures, charts, and tables. Final quality control auditing was performed to ensure the accuracy and consistency of data across the dataset, including the sampling of 25% of all extracted data for quality assurance. A study quality appraisal was conducted using the Cochrane Collaboration Risk of Bias Assessment Tool for systematic reviews \[[@CR13]\] to evaluate seven domains of bias: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias (other bias).

Data Synthesis and Analysis {#Sec7}
---------------------------

Direct (pair-wise) meta-analyses were conducted comparing ezetimibe therapy plus background LLT versus the same background LLT (which could have been no background LLT); all analyses were performed using the "metafor" package in R software version 3.5.1 \[[@CR14]\]. Analyses of overall estimates of effect sizes used the random-effects model of DerSimonian and Laird \[[@CR13]\]. Heterogeneity of effect size was assessed with the *Q* test statistic \[[@CR13]\], using cut-off values of 25%, 50%, and 75% to assign low, moderate, and high degrees of heterogeneity, respectively. Comparisons of heterogeneity between meta-analyses were performed based on the *I*^2^ statistic \[[@CR13]\].

The primary analysis compared the mean LDL-C change from baseline between combination ezetimibe plus background LLT versus background LLT comparator for all studies at 6 months or at the reported timepoint closest to 6 months. Sensitivity analyses included the assessment of the LDL-C change from baseline over shorter (1--3 months) or longer (9--12 months) durations. A sensitivity analysis with the largest trial removed was also conducted because of its disproportionately high weight in the primary analysis. Separate analyses for trials enrolling patients who were statin naïve versus those with a history of statin use were also conducted. In addition, analyses were performed on the subgroup of trials that only enrolled patients with recent (\< 1 year) ACS.

Results {#Sec8}
=======

Studies Identified Through the Systematic Literature Review {#Sec9}
-----------------------------------------------------------

The systematic review flow diagram is shown in Fig. [1](#Fig1){ref-type="fig"}. A total of 14 records matching the eligibility criteria were identified through the systematic literature review (refer to Tables S4 and S5 in the ESM for a summary of studies included). Of these, 12 records reported the primary outcome of either LDL-C change from baseline or LDL-C level at the endpoint, or both, and had adequate independent information available that could be used for the meta-analysis. The justifications recorded for the inclusion/exclusion of the identified records are summarized in Tables S4 and S5 in the ESM; the resulting 12 studies included in the meta-analysis are listed in Table [1](#Tab1){ref-type="table"}, along with study design, treatment arms, duration, baseline demographic characteristics, and baseline LDL-C values for each study.Fig. 1Study flow diagram of the systematic review. Overall, 14 records were identified through the systematic literature review that reported on patients with ASCVD, that assessed ezetimibe therapy (received with or without other lipid-lowering therapies), and reported LDL-C change, LDL-C at endpoint, or both. Of these, 12 records contained adequate and independent information sufficient for meta-analysis, including nine reporting on two-arm trials and three reporting on multi-arm trials. ^a^115 records were manually entered, and four additional records were cited in protocols. *ASCVD* atherosclerotic cardiovascular disease, *LDL-C* low-density lipoprotein cholesterolTable 1Demographics and baseline characteristics of patients included in the meta-analysis according to study and treatment groupStudy (trial number)Study designTreatment armsTreatment period (follow-up period)Randomized patients, *n*Age, yearsFemale sexCaucasianJapanese ethnicityLDL-C, (mg/Dl)Brohet et al. (2005) \[[@CR26]\]Randomized, double-blind, placebo-controlled, multi-armEZE 10 mg QD + SIM 10/20 mg QD6 weeks (no additional follow-up)20863.6 ± 11.163 (30.3)121.8 ± 16.2SIM 10/20 mg QD21062.7 ± 9.652 (24.8)123.0 ± 13.9EZE 10 mg QD + SIM 10 mg QD65117.9EZE 10 mg QD + SIM 20 mg QD143123.7SIM 10 mg QD72121.8SIM 20 mg QD138123.4Cannon et al. (2015) \[[@CR12]\] IMPROVE-IT (NCT00202878)^a^Randomized, double-blind, controlled, two-armEZE 10 mg QD + SIM 40--80 mg QDMedian 6 years (no additional follow-up)906763.6 ± 9.72225 (24.5)7578 (83.6)93.8SIM 40--80 mg QD907763.6 ± 9.82191 (24.1)7624 (84.0)93.8Hibi et al. (2018) \[[@CR27]\] (NCT00549926)^a,\ b^Randomized, open-label, controlled, two-armEZE 10 mg QD + PITA 2 mg QD10 months (no additional follow-up)50^c^63 ± 10.09 (18.0)123 ± 32.0PITA 2 mg QD53^c^63 ± 12.012 (22.6)126 ± 33.0Joshi et al. (2017) \[[@CR28]\]^b^Randomized, controlled, two-armEZE 10 mg QD + ROSU 10 mg QD24 weeks (no additional follow-up)4060.3 ± 9.818 (45.0)162.7 ± 23.1ROSU 10 mg QD4059.8 ± 11.115 (37.5)153.4 ± 24.8Masuda et al. (2015) \[[@CR29]\] (UMIN000010323)Randomized, open-label, controlled, two-armEZE 10 mg QD + ROSU 5 mg QD6 months (no additional follow-up)21^c^64.0 ± 7.92 (9.5)021 (100)131.8 ± 25.6ROSU 5 mg QD19^c^70.2 ± 7.63 (15.8)019 (100)123.0 ± 27.0Ran et al. (2017) \[[@CR30]\]^a,\ b^Randomized, controlled, multi-armEZE 10 mg QD + ROSU 10 mg QD12 weeks (no additional follow-up)4260.4 ± 8.210 (23.8)141 ± 27.0ROSU 10 mg QD4260.6 ± 6.711 (26.2)141 ± 33.0ROSU 20 mg QD4160.5 ± 10.011 (26.8)141 ± 35.0Ren et al. (2017) \[[@CR31]\]^a^Randomized, controlled, two-armEZE 10 mg QD + ROSU 10 mg QD12 months (no additional follow-up)5557.3 ± 1.57 (12.7)116.0 ± 37.1ROSU 10 mg QD5860.7 ± 1.312 (20.7)113.3 ± 39.4Ueda et al. (2017) \[[@CR32]\] ZIPANGU (UMIN000006971)Randomized, open-label, controlled, two-armEZE 10 mg QD + ATOR 10--20 mg QD9 months (no additional follow-up)54^c^71 ± 8.013 (24.1)101 ± 27.0ATOR 10--20 mg QD54^c^68 ± 11.010 (18.5)100 ± 27.0Wang et al. (2017) \[[@CR33]\]Randomized, controlled, two-armEZE 10 mg QD + ATOR 20 mg QD12 months (no additional follow-up)5158 ± 10.020 (39.2)136.5 ± 33.6ATOR 20 mg QD4958 ± 9.019 (38.8)133.4 ± 29.0Wang et al. (2016) \[[@CR34]\]^b^Randomized, controlled, two-armEZE 10 mg QD + ROSU 10 mg QD12 months (no additional follow-up)50^c^63 ± 10.014 (28.0)140.0 ± 45.6ROSU 10 mg QD48^c^65 ± 12.013 (27.1)134.6 ± 48.7West et al. (2011) \[[@CR35]\] (NCT00587678)^b^Randomized, double-blind;^b^ open-labelEZE 10 mg QD + SIM 40 mg QD2 years (no additional follow-up)18^c^62 ± 8.08 (44.4)14 (78.0)118 ± 38.1SIM 40 mg QD16^c^59 ± 10.05 (31.3)13 (81.0)118 ± 40.0EZE 10 mg QD33^c^65 ± 10.017 (51.5)24 (73.0)100 ± 23.0Zou et al. (2016) \[[@CR36]\]^b^Randomized, controlled, two-armEZE 10 mg QD + ATOR 10 mg QD12 months (no additional follow-up)4069.3 ± 5.8ATOR 10 mg QD4070.3 ± 7.2Data are presented as mean ± standard deviation or *N* (%) unless otherwise indicated*ATOR* atorvastatin, *EZE* ezetimibe, *LDL-C* low-density lipoprotein cholesterol, *NR* not reported, *PITA* pitavastatin, *QD* daily, *ROSU* rosuvastatin, *SIM* simvastatin^a^Trials included in sensitivity analysis of patients with recent acute coronary syndrome (\< 1 year)^b^Studies including statin-naïve patients at enrolment^c^Patient population defined as follows: Hibi et al. \[[@CR27]\], randomized patients included in the full analysis set; Masuda et al. \[[@CR29]\], randomized patients included in the primary analysis; Ueda et al. \[[@CR32]\], randomized patients who were included in the analysis; Wang et al. \[[@CR34]\], randomized patients included in the analysis; West et al. \[[@CR35]\], randomized patients included in the analysis

Although the objective was to assess LDL-C lowering with ezetimibe therapy received with or without other LLTs compared with the same background LLTs, all included studies compared combination ezetimibe plus statin therapy with statin monotherapy. Across the studies, the mean age of participants ranged from 57 to 71 years according to treatment group (Table [1](#Tab1){ref-type="table"}). A key difference between the 12 studies was the definition of cardiovascular history used as an inclusion criterion, as summarized in Table S6 in the ESM. The primary LDL-C outcomes of interest reported in the included studies are summarized in Table S7 in the ESM.

Across the 12 trials, the risk of selection bias was mainly unclear for random sequence generation and allocation concealment, as authors did not describe the randomization methodology in sufficient detail. The risk of selection bias was mainly low for random sequence generation and unclear for allocation concealment as authors did not describe the randomization methodology in enough detail. The risk of performance bias, pertaining to blinding of participants and personnel, was assessed as high among four trials, low among two trials, and unclear among six trials. The risk of detection bias, pertaining to blinding of outcome assessment, was rated as high for one trial. The risk of attrition bias (pertaining to incomplete outcome data) and the risk of reporting bias (pertaining to selective reporting of outcomes) was predominantly low across all trials. The risk of other sources of bias was predominantly unclear across all trials. A summary of the risk of bias across the 12 trials is provided in Table S8 in the ESM.

Efficacy of Low-Density Lipoprotein Cholesterol Lowering of Ezetimibe {#Sec10}
---------------------------------------------------------------------

A forest plot showing the primary outcome of interest, LDL-C change from baseline, with combination ezetimibe plus statin therapy versus statin monotherapy, is presented in Fig. [2](#Fig2){ref-type="fig"} for the main analysis of data collected at 6 months (or at the reported timepoint closest to 6 months). Overall, patients receiving combination ezetimibe were likely to experience an additional decrease in LDL-C (− 21.86 mg/dL; 95% confidence interval \[CI\] − 26.56 to − 17.17; *p *\< 0.0001) compared with those receiving statin monotherapy. Sensitivity analyses of trials based on time of reporting of LDL-C change showed similar results for both shorter (1--3 months), at 6 months, and longer (9--12 months) treatment durations (overall LDL-C mean difference − 21.49 mg/dL; 95% CI − 28.45 to − 14.53, *p *\< 0.0001 at 1 month; − 19.96 mg/dL; 95% CI − 28.07 to − 11.85, *p* \< 0.0001 at 3 months; − 20.75 mg/dL; 95% CI − 26.92 to − 14.58, *p *\< 0.0001 at 6 months; and − 19.36 mg/dL; 95% CI − 24.42 to − 14.30, *p *\< 0.0001 at 9--12 months; Figs. S1, S2, S3, and S4, respectively \[see the ESM\]). A sensitivity analysis removing the study by Cannon et al. \[[@CR12]\] yielded a similar result (LDL-C mean difference − 22.84 mg/dL; 95% CI − 27.40 to − 18.28, *p *\< 0.0001 at 6 months or at the reported timepoint closest to 6 months).Fig. 2Treatment difference in mean LDL-C change (mg/dL) from baseline between combination ezetimibe plus statin therapy and statin monotherapy comparator at 6 months or at the reported timepoint closest to 6 months. ^a^Meta-analysis included 19,404 participants from 12 studies, who received treatment (ezetimibe + statin vs. statin) for a mean duration of 11.56 months. \**p *\< 0.0001. *CI* confidence interval, *LDL-C* low-density lipoprotein cholesterol, *MD* mean difference, *RE* random effects

Analyses of studies according to whether patients were statin naïve or had a history of statin therapy at enrollment showed that patients receiving combination ezetimibe plus statin therapy had greater LDL-C reduction than those receiving statin monotherapy, irrespective of prior history of statin therapy (mean difference − 25.07 mg/dL; 95% CI − 31.73 to − 18.41 and − 19.54 mg/dL; 95% CI − 25.56 to − 13.53, respectively; Fig. S5 in the ESM). There was no significant difference between the two groups (*p* = 0.2462).

Subgroup Analysis of Patients with a History of Recent Acute Coronary Syndrome {#Sec11}
------------------------------------------------------------------------------

Similar to the results in overall population, analyses of the subpopulation with recent (\< 1 year) ACS showed that patients receiving combination ezetimibe plus statin were more likely to experience a decrease in LDL-C levels than those receiving statin monotherapy (LDL-C mean difference of − 19.19 mg/dL; 95% CI − 25.22 to − 13.16, *p *\< 0.0001; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Subgroup analysis: LDL-C change (mg/dL) from baseline at 6 months, or at the reported timepoint closest to 6 months, limited to studies including patients with recent acute (\< 1 year) coronary syndrome (Meta-analysis included 18,436 participants from four studies, who received treatment \[ezetimibe plus statin vs. statin\] for a mean duration of 11.90 months). \**p *\< 0.0001. *CI* confidence interval, *LDL-C* low-density lipoprotein cholesterol, *MD* mean difference, *RE* random effects

Discussion {#Sec12}
==========

Although previous studies have assessed the efficacy and safety of ezetimibe \[[@CR15]--[@CR20]\], this study is the first systematic literature review and meta-analysis of LDL-C lowering with ezetimibe in patients with ASCVD since the results of the IMPROVE-IT cardiovascular outcomes trial were published. In the present analysis, combination ezetimibe plus statin therapy resulted in a modest (relative to other treatment options) additional decrease in LDL-C compared with statin monotherapy (LDL-C mean difference − 21.86 mg/dL after 6 months of treatment), which was unaffected by treatment duration or a patient's prior history of statin therapy. Results were similar for patients with a recent ACS event (LDL-C mean difference of − 19.19 mg/dL). These results are consistent with the 19--23% LDL-C reduction reported previously for ezetimibe when added to statin therapy \[[@CR10], [@CR11]\].

The dose-dependent association between absolute LDL-C level and cardiovascular risk has been consistently demonstrated across statin trials. In the CTTC (Cholesterol Treatment Trialists Collaboration) study, a reduction of approximately 22% in major vascular events occurred per 1 mmol/L (38.7 mg/dL) lowering of LDL-C level. The incremental reduction in LDL-C with ezetimibe when added to statin therapy may not be sufficient for patients at very high risk of cardiovascular events and with LDL-C levels more than 20--25 mg/dL from the desired threshold despite optimal statin use. Furthermore, the relatively low variability in patient response to ezetimibe observed in these analyses suggests that it may not be enough for those with very high LDL-C levels. In such patients, there may be a need to consider other non-statin LLTs, including PCSK9 inhibitors \[[@CR21]\]. A 2019 National Lipid Association statement identified specific patient subgroups for whom it may be optimal to directly initiate a PCSK9 inhibitor based on potentially insufficient LDL-C and risk reduction on ezetimibe alone \[[@CR22]\].

Similar considerations may also be important in patients with recent ACS because of the high risk for subsequent events in the months following an event \[[@CR12], [@CR23]\]. LDL-C reduction results from the analysis of the recent ACS population reported here were consistent with the IMPROVE-IT cardiovascular outcomes trial \[[@CR12]\] as well as the primary analysis reported here (general ASCVD population). The results remained similar in a sensitivity analysis with IMPROVE-IT removed.

Overall, results were also similar to those of other past studies. LDL-C lowering was consistent with that reported in previous studies including RCTs that did not meet our inclusion criteria and pooled analyses \[[@CR11], [@CR24]\]. The low variability of LDL-C lowering with the addition of ezetimibe to statin therapy is in line with a previous report by Descamps et al. \[[@CR25]\].

A limitation of the present analysis is that differences in clinical attributes of studied populations may introduce unmeasurable biases (participant cardiovascular inclusion criteria for each study are summarized in Table S6 in the ESM). There may also be potential publication bias in terms of which studies may have been published, but there is no clear way to quantify these potential biases. On the other hand, access to multiple clinical studies permits examination from a broader evidence base than provided through the analysis of a single clinical trial. A patient-level meta-analysis would complement these results, although gaining access to such data would be challenging.

Conclusions {#Sec13}
===========

The evidence from this systematic literature review and meta-analyses showed that patients with ASCVD receiving combination ezetimibe plus statin therapy experienced an additional 22 mg/dL reduction in LDL-C compared with patients receiving statin therapy alone. The modest incremental reduction in LDL-C suggests that patients with ASCVD and LDL-C levels more than 20--25 mg/dL from the desired threshold despite statin therapy may need other LLT options such as PCSK9 inhibitors.
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